NO20084291L - 2,6-substituert-4-monosubstituert aminopyridin som prostaglandin D2 reseptor-antagonister - Google Patents
2,6-substituert-4-monosubstituert aminopyridin som prostaglandin D2 reseptor-antagonisterInfo
- Publication number
- NO20084291L NO20084291L NO20084291A NO20084291A NO20084291L NO 20084291 L NO20084291 L NO 20084291L NO 20084291 A NO20084291 A NO 20084291A NO 20084291 A NO20084291 A NO 20084291A NO 20084291 L NO20084291 L NO 20084291L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutically acceptable
- accompanied
- urticaria
- itching
- solvate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
Abstract
Foreliggende oppfinnelse angår en forbindelse med formel (I) hvori Rog Rer som definert heri, eller et farmasøytisk akseptabelt salt, hydrat eller solvat derav, et farmasøytisk akseptabelt prodmg derav eller et farmasøytisk akseptabelt salt, hydrat eller solvat av prodmget, en farmasøytisk sammensetning som innbefatter en farmasøytisk effektiv mengde av en eller flere forbindelser ifølge oppfinnelsen blandet med en farmasøytisk akseptabel bærer, en fremgangsmåte for behandling av en pasient som lider av en PGD2 forstyrrelse som inkluderer, men er ikke begrenset til, allergisk sykdom (slik som allergisk rinitt, allergisk konjunktivitt, topisk dermatitt, bronkial astma og matallergi), systemisk mastocytose, forstyrrelser ledsaget av systemisk mastcelleaktivering, anafylaksisjokk, bronkokonstriksjon, bronkitt, urtikari, eksem, sykdommer ledsaget av kløe (slik som atopisk dermatitt og urtikari), sykdommer (slike som katarakt, retinal løsning, inflammasjon, infeksjon og søvnforstyrrelser) som genereres sekundært som et resultat av atferd ledsaget av kløen, (slik som skraping og banking), inflammasjon, kronisk obstruktiv lungesykdom, iskemisk reperfunksjonsskade, cerebrovaskulær ulykke, kronisk reumatoid artritt, pleurisy, ulcerativ kolitt og lignende ved administrering til nevnte pasient en farmasøytisk effektiv mengde av en forbindelse ifølge oppfinnelsen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74467606P | 2006-04-12 | 2006-04-12 | |
PCT/US2007/066481 WO2007121280A1 (en) | 2006-04-12 | 2007-04-12 | 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin d2 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20084291L true NO20084291L (no) | 2008-11-11 |
Family
ID=38294040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20084291A NO20084291L (no) | 2006-04-12 | 2008-10-14 | 2,6-substituert-4-monosubstituert aminopyridin som prostaglandin D2 reseptor-antagonister |
Country Status (26)
Country | Link |
---|---|
US (1) | US20090036469A1 (no) |
EP (1) | EP2010503A1 (no) |
JP (1) | JP2009533473A (no) |
KR (1) | KR20080108287A (no) |
CN (1) | CN101421252B (no) |
AR (1) | AR060403A1 (no) |
AU (1) | AU2007238052B2 (no) |
BR (1) | BRPI0710710A2 (no) |
CA (1) | CA2649083C (no) |
CR (1) | CR10249A (no) |
DO (1) | DOP2007000068A (no) |
EC (1) | ECSP088813A (no) |
HK (1) | HK1131975A1 (no) |
HN (1) | HN2008001530A (no) |
MA (1) | MA30409B1 (no) |
MX (1) | MX2008011369A (no) |
NO (1) | NO20084291L (no) |
NZ (1) | NZ571793A (no) |
PE (1) | PE20080186A1 (no) |
RU (1) | RU2431631C2 (no) |
TN (1) | TNSN08339A1 (no) |
TW (1) | TW200815395A (no) |
UA (1) | UA95950C2 (no) |
UY (1) | UY30283A1 (no) |
WO (1) | WO2007121280A1 (no) |
ZA (1) | ZA200807380B (no) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5039594B2 (ja) * | 2008-02-08 | 2012-10-03 | 株式会社日立ハイテクノロジーズ | レビュー装置,検査領域設定支援システム、および、欠陥の画像得方法 |
AR074776A1 (es) * | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
RU2012143897A (ru) * | 2010-03-16 | 2014-04-27 | Авентис Фармасьютикалз Инк. | Замещенные пиримидины как антагонисты рецепторов простагландина d2 |
JP2013522307A (ja) * | 2010-03-16 | 2013-06-13 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | プロスタグランジンd2受容体アンタゴニストとしての置換ピリミジン |
WO2012004722A1 (en) | 2010-07-05 | 2012-01-12 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
EP2621276B1 (en) * | 2010-09-30 | 2017-12-27 | Merck Sharp & Dohme Corp. | 2-alkoxy pyrimidine pde10 inhibitors |
RU2014129613A (ru) | 2011-12-21 | 2016-02-10 | Актелион Фармасьютиклз Лтд | Гетероциклильные производные и их применение в качестве модуляторов рецептора простагландина d2 |
CN104428305A (zh) | 2012-07-05 | 2015-03-18 | 埃科特莱茵药品有限公司 | 1-苯基-取代的杂环衍生物及其作为前列腺素d2受体调节剂的用途 |
EP3382391A1 (en) | 2012-10-24 | 2018-10-03 | NYU Winthrop Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
EP3067349B1 (en) * | 2013-11-08 | 2018-02-28 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
WO2016020288A1 (en) | 2014-08-04 | 2016-02-11 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
TW201900178A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 作為pge2受體調節劑之嘧啶衍生物 |
CN110621671A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物 |
ES2896476T3 (es) | 2017-05-18 | 2022-02-24 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
HUE056080T2 (hu) | 2017-05-18 | 2022-01-28 | Idorsia Pharmaceuticals Ltd | Fenilszármazékok mint PGE2 receptor modulátorok |
KR20200109293A (ko) | 2017-09-13 | 2020-09-22 | 프로제너티, 인크. | 자간전증 바이오마커 및 관련된 시스템 및 방법 |
EP4029380A4 (en) * | 2019-09-13 | 2023-09-13 | Meiji Co., Ltd | SOLID FOOD, AND SOLID MILK |
EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
EP4076657A1 (en) | 2019-12-20 | 2022-10-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
CA3174176A1 (en) | 2020-03-31 | 2021-10-07 | Sanne Schroder Glad | Compounds active towards nuclear receptors |
MX2022012260A (es) | 2020-03-31 | 2022-11-30 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3644799A1 (de) * | 1986-06-04 | 1987-12-10 | Hoechst Ag | Neue pyrimidin-derivate, deren herstellung und verwendung |
SE0200411D0 (sv) * | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
HN2005000795A (es) * | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
GT200600457A (es) * | 2005-10-13 | 2007-04-27 | Aventis Pharma Inc | Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2 |
-
2007
- 2007-04-10 DO DO2007000068A patent/DOP2007000068A/es unknown
- 2007-04-10 AR ARP070101501A patent/AR060403A1/es not_active Application Discontinuation
- 2007-04-12 EP EP07760526A patent/EP2010503A1/en not_active Withdrawn
- 2007-04-12 BR BRPI0710710-2A patent/BRPI0710710A2/pt not_active IP Right Cessation
- 2007-04-12 TW TW096112790A patent/TW200815395A/zh unknown
- 2007-04-12 MX MX2008011369A patent/MX2008011369A/es active IP Right Grant
- 2007-04-12 JP JP2009505615A patent/JP2009533473A/ja not_active Abandoned
- 2007-04-12 NZ NZ571793A patent/NZ571793A/en not_active IP Right Cessation
- 2007-04-12 UA UAA200813109A patent/UA95950C2/ru unknown
- 2007-04-12 UY UY30283A patent/UY30283A1/es not_active Application Discontinuation
- 2007-04-12 RU RU2008144578/04A patent/RU2431631C2/ru not_active IP Right Cessation
- 2007-04-12 AU AU2007238052A patent/AU2007238052B2/en not_active Expired - Fee Related
- 2007-04-12 CA CA2649083A patent/CA2649083C/en not_active Expired - Fee Related
- 2007-04-12 KR KR1020087024764A patent/KR20080108287A/ko not_active Application Discontinuation
- 2007-04-12 PE PE2007000450A patent/PE20080186A1/es not_active Application Discontinuation
- 2007-04-12 CN CN2007800127354A patent/CN101421252B/zh not_active Expired - Fee Related
- 2007-04-12 WO PCT/US2007/066481 patent/WO2007121280A1/en active Application Filing
-
2008
- 2008-08-26 CR CR10249A patent/CR10249A/es not_active Application Discontinuation
- 2008-08-27 TN TNP2008000339A patent/TNSN08339A1/en unknown
- 2008-08-27 ZA ZA200807380A patent/ZA200807380B/xx unknown
- 2008-10-07 US US12/246,918 patent/US20090036469A1/en not_active Abandoned
- 2008-10-09 EC EC2008008813A patent/ECSP088813A/es unknown
- 2008-10-10 HN HN2008001530A patent/HN2008001530A/es unknown
- 2008-10-14 NO NO20084291A patent/NO20084291L/no not_active Application Discontinuation
- 2008-11-10 MA MA31375A patent/MA30409B1/fr unknown
-
2009
- 2009-10-28 HK HK09110008.0A patent/HK1131975A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2010503A1 (en) | 2009-01-07 |
DOP2007000068A (es) | 2007-10-31 |
CN101421252A (zh) | 2009-04-29 |
HK1131975A1 (en) | 2010-02-12 |
AU2007238052B2 (en) | 2011-12-22 |
TW200815395A (en) | 2008-04-01 |
ZA200807380B (en) | 2009-05-27 |
ECSP088813A (es) | 2008-11-27 |
NZ571793A (en) | 2011-08-26 |
UA95950C2 (en) | 2011-09-26 |
HN2008001530A (es) | 2012-01-17 |
RU2431631C2 (ru) | 2011-10-20 |
US20090036469A1 (en) | 2009-02-05 |
WO2007121280A1 (en) | 2007-10-25 |
MA30409B1 (fr) | 2009-05-04 |
KR20080108287A (ko) | 2008-12-12 |
CR10249A (es) | 2008-11-26 |
BRPI0710710A2 (pt) | 2011-08-16 |
JP2009533473A (ja) | 2009-09-17 |
CN101421252B (zh) | 2011-10-12 |
AR060403A1 (es) | 2008-06-11 |
AU2007238052A1 (en) | 2007-10-25 |
MX2008011369A (es) | 2008-09-18 |
RU2008144578A (ru) | 2010-05-20 |
CA2649083C (en) | 2011-06-28 |
TNSN08339A1 (en) | 2009-12-29 |
CA2649083A1 (en) | 2007-10-25 |
PE20080186A1 (es) | 2008-04-15 |
UY30283A1 (es) | 2007-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20084291L (no) | 2,6-substituert-4-monosubstituert aminopyridin som prostaglandin D2 reseptor-antagonister | |
NO20072440L (no) | 2,6-substituert-4-monosubstituertamino-pyrimidin som prostaglanding D2 reseptor antagonister | |
MY145648A (en) | Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist | |
BRPI0607079A2 (pt) | 2-fenil-indóis como antagonistas de receptor de prostaglandina d2 | |
NO20090862L (no) | 2-fenyl-indoler som prostaglandin D2-reseptorantagonister | |
NO20024281L (no) | Indolderivater, fremgangsmÕte for fremstilling av de samme og anvendelse derav | |
BRPI0511344A (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto combinado | |
WO2005021515A3 (en) | Inhibitors of phosphodiesterase type-iv | |
NO20076450L (no) | Heterosykliske forbindelser som nikotinsyrereseptoragonister for behandling av dyslipidemi | |
NO20070076L (no) | Nye indazolkarboksamider og deres anvendelse | |
NO20090139L (no) | Substituted phenyl acetic acids as DP-2 antagonists | |
NO20061207L (no) | Karboksylsyreforbindelser og medisinske preparater inneholdende de samme som den aktive bestanddel | |
EA200900472A1 (ru) | Ингибиторы фосфодиэстеразы iv типа | |
WO2006085212A3 (en) | Condensed isoxaline derivatives as inhibitors of phosphodiesterase type-iv | |
NO20080457L (no) | Kjemiske forbindelser | |
TW200635932A (en) | New pyridothienopyrimidine derivatives | |
NO20073436L (no) | Nye heterosykliske forbindelser nyttige for behandling av inflammatoriske og allergiske forstyrrelser | |
UA95303C2 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
WO2007046022A3 (en) | Inhibitors of phosphodiesterase type-iv | |
CY1113582T1 (el) | 2,6-υποκατεστημενες-4-μονοϋποκατεστημενες amino-πυριμιδινες ως ανταγωνιστες υποδοχεων d2 των προσταγλανδινων |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |